

PATENT
2507-1003

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re application of: Antonio FACCHIANO et al.

Appl. No.: Group:

Filed: February 20, 2002 Examiner:

For: PEPTIDE INHIBITING PLATELET DERIVED GROWTH
FACTOR (PDGF-BB) AND FIBROBLAST GROWTH FACTOR (bFGF) ACTIVITY

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

February 20, 2002

Sir:

The following preliminary amendments and remarks are respectfully submitted in connection with the above-identified application.

IN THE CLAIMS:

Please amend the claims as follows:

5. (amended) The use of the peptides of claim 1 as inhibitors of platelet derived growth factor (PDGF-BB) and fibroblast growth factor (bFGF).

6. (amended) The use of the peptides of claim 1 for the preparation of a pharmacological compound able to affect cell proliferation.

7. (amended) The use of the peptides of claim 1 for the preparation of a pharmacological compound able to affect cell migration and tumor cell migration toward potential metastasis sites.

8. (amended) The use of the peptides of claim 1 as inhibitors of primary tumor growth and metastasis.

9. (amended) The use of the peptides of claim 1 for the preparation of a pharmacological compound to be used as adjuvant for the treatment of neoplastic and vascular diseases.

10. (amended) The use of the peptides of claim 1 for the preparation of a pharmacological compound to be used for the treatment of vascular diseases.

11. (amended) The use of the peptides of claim 1 for the preparation of a pharmacological compound to be used for the treatment of trombotic events and related pathologies.

REMARKS

Claims 1-11 are pending in the present application.

Entry of the above amendments is earnestly solicited.

An early and favorable first action on the merits is earnestly requested.

Should there be any matters that need to be resolved in the present application, the Examiner is respectfully requested to contact the undersigned at the telephone number listed below.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON

Benoit Castel

Benoit Castel, Reg. No. 35,041

745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297

BC/ia
Attachments

VERSION WITH MARKINGS TO SHOW CHANGES MADEIN THE CLAIMS:

The claims have been amended as follows:

5. (amended) The use of the peptides of ~~claims 1 or 2 or 3~~ or ~~4~~ claim 1 as inhibitors of platelet derived growth factor (PDGF-BB) and fibroblast growth factor (bFGF).
6. (amended) The use of the peptides of ~~claims 1 or 2 or 3~~ or ~~4~~ claim 1 for the preparation of a pharmacological compound able to affect cell proliferation.
7. (amended) The use of the peptides of ~~claims 1 or 2 or 3~~ or ~~4~~ claim 1 for the preparation of a pharmacological compound able to affect cell migration and tumor cell migration toward potential metastasis sites.
8. (amended) The use of the peptides of ~~claims 1 or 2 or 3~~ or ~~4~~ claim 1 as inhibitors of primary tumor growth and metastasis.
9. (amended) The use of the peptides of ~~claims 1 or 2 or 3~~ or ~~4~~ claim 1 for the preparation of a pharmacological compound to be used as adjuvant for the treatment of neoplastic and vascular diseases.
10. (amended) The use of the peptides of ~~claims 1 or 2 or 3~~ or ~~4~~ claim 1 for the preparation of a pharmacological compound to be used for the treatment of vascular diseases.
11. (amended) The use of the peptides of ~~claims 1 or 2 or 3~~ or ~~4~~ claim 1 for the preparation of a pharmacological compound to be

used for the treatment of trombotic events and related pathologies.